Pharmaceutical News and Articles

After Weighting, 3.6 Million Likely to Be Newly Eligible for Semaglutide

Increases in eligibility for semaglutide are discussed in a research letter published online Aug. 27 in the Annals of Internal Medicine.After the Semaglutide Ef

GSK Receives US FDA Breakthrough Therapy Designation for B7-H3-Targeted Antibody-Drug Conjugate GSK5764227 in Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer

GSK plc (LSE NYSE GSK) announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for GSK5764227 (GSK 227), the

Tirzepatide Reduced the Risk of Developing Type 2 Diabetes by 94% in Adults with Pre-Diabetes and Obesity or Overweight

INDIANAPOLIS, Aug. 20, 2024. Eli Lilly and Company (NYSE LLY) announced today positive topline results from the SURMOUNT-1 three-year study (176-week treatment

Bayer Initiates Phase II Study of Soluble Guanylate Cyclase Activator (BAY3283142) in Patients with Chronic Kidney Disease

Berlin, Germany, August 22, 2024 Bayer announced today the start of the ALPINE-1 study, a Phase II clinical trial with BAY3283142, an investigational soluble gu

The Journal of American Medical Association (JAMA) Publishes Elinzanetant Phase III Data

Berlin, August 22, 2024 Data published in The Journal of the American Medical Association (JAMA) from the pivotal Phase III studies OASIS 1 and 2, evaluating th

Mabwell Announces the CDE Approval of Novel Nectin-4 Targeting ADC to Initiate Phase III Clinical Trial for the Treatment of Cervical Cancer

SHANGHAI, Aug. 23, 2024. Mabwell an innovative biopharmaceutical company with entire industry chain, announced that its submission to the Center for Drug Evalua

Lykos Therapeutics Announces Complete Response Letter for Midomafetamine Capsules for PTSD

LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia

Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns

U.S. Food and Drug Administration Accepts for Priority Review Deciphera’s New Drug Application for Vimseltinib for the Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)